BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)

NCT01376102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 657

Last updated 2014-06-16

No results posted yet for this study

Summary

This is an open label, multi-centre, non-interventional post-marketing surveillance

Conditions

Interventions

DRUG

BONVIVA(ibandronate) injection

Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376102 on ClinicalTrials.gov